Company Filing History:
Years Active: 2010
Title: Kimmo Vihko: Innovator in Steroid Hormone Research
Introduction
Kimmo Vihko is a notable inventor based in Turku, Finland. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target steroid hormone-dependent disorders. His work has implications for the treatment and prevention of various diseases.
Latest Patents
Vihko holds a patent for "Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds." This patent focuses on thiophenepyrimidinone compounds that are useful in therapy, especially for conditions requiring the inhibition of the 17β-hydroxysteroid dehydrogenase enzyme. This includes types 1, 2, or 3 of the enzyme, which play a crucial role in steroid hormone metabolism.
Career Highlights
Kimmo Vihko is associated with Solvay Pharmaceuticals B.V., where he has been involved in groundbreaking research. His work has contributed to advancements in understanding steroid hormone functions and their implications in various health conditions.
Collaborations
Some of his notable coworkers include Kristiina Waehaelae and Annamaria Lilienkampf. Their collaborative efforts have furthered research in the field and enhanced the development of innovative therapeutic solutions.
Conclusion
Kimmo Vihko's contributions to pharmaceutical research, particularly in the area of steroid hormone inhibitors, highlight his role as an influential inventor. His patent and collaborative work continue to pave the way for advancements in medical treatments.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.